Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.88 |
| ▸ | BLM | P54132 | 2/20 | 0.88 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.88 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taurine SCHEMBL23068 | 0.94 | — | — | |
| Taurine SCHEMBL30179154 | 0.94 | — | — | |
| Taurine SCHEMBL42632 | 0.94 | BLM (1.00) | LMNABLMSLC6A6CYP2C19APP | |
| Taurine SCHEMBL30191395 | 0.94 | — | — | |
| Taurine SCHEMBL10626136 | 0.90 | — | — | |
| Taurine SCHEMBL3667691 | 0.90 | — | — | |
| Taurine SCHEMBL11449240 | 0.90 | — | — | |
| Taurine SCHEMBL466027 | 0.90 | — | — | |
| Taurine SCHEMBL1100954 | 0.90 | — | — | |
| Taurine SCHEMBL8052521 | 0.90 | BLM (0.93) | LMNABLMSLC6A6CYP2C19APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133678-A1 | BIFIDOBACTERIUM LONGUM STRAIN BIOCC1719 DSM 34239 AND ITS USE AS FOOD SUPPLEMENT, BEVERAGE ADDITIVE AND FOR FUNCTIONAL FOOD | BIOCC OÜ (EE) | 2025-06-26 | — | — | WO | disclosed |
| US-20130085469-A1 | TAUROLIDINE FORMULATIONS AND DELIVERY: THERAPEUTIC TREATMENTS AND ANTIMICROBIAL PROTECTION AGAINST BACTERIAL BIOFILM FORMATION | CORMEDIX INC. | 2013-04-04 | — | — | US | disclosed |
| EP-1509231-B1 | System for peritoneal dialysis comprising a reservoir of dialysis solution and a cartridge containing taurolidine powder | ND PARTNERS LLC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7820651-B2 | Preparation of antimicrobial formulations using 7-oxa-2-thia-1,5-diazabicyclo[3.3.1]nonane-2,2-dione | HERDEIS CLAUS | 2010-10-26 | — | — | US | disclosed |
| US-20080177217-A1 | Taurolidine Formulations and Delivery: Therapeutic Treatments and Antimicrobial Protection Against Bacterial Biofilm Formation | CORMEDIX INC. | 2008-07-24 | — | — | US | disclosed |
| WO-2008011980-A1 | PREPARATION OF ANTIMICROBIAL FORMULATIONS USING 7-OXA-2-THIA-1,5-DIAZABICYCLO[3.3.1]NONANE-2,2-DIONE | HERDEIS CLAUS (DE) | 2008-01-31 | — | — | WO | disclosed |
| US-20080027043-A1 | PREPARATION OF ANTIMICROBIAL FORMULATIONS USING 7-OXA-2-THIA-1,5-DIAZABICYCLO[3.3.1]NONANE-2,2-DIONE | HERDEIS CLAUS | 2008-01-31 | — | — | US | disclosed |
| EP-1509231-A4 | PERITONEAL DIALYSIS SOLUTION WITH TAUROLIDINE | ND PARTNERS LLC (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1647276-A1 | Use of taurolidine formulations for the intramammary treatment of mastitis | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005115357-A2 | TAUROLIDINE FORMULATIONS AND DELIVERY | POLASCHEGG HANS-DIETRICH (AT) | 2005-12-08 | — | — | WO | disclosed |
| CN-1655791-A | Peritoneal dialysis solution containing taurolidine | ND PARTNERS LLC (US) | 2005-08-17 | — | — | CN | disclosed |
| EP-1509231-A1 | PERITONEAL DIALYSIS SOLUTION WITH TAUROLIDINE | ND Partners, LLC (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6803363-B2 | Peritoneal dialysis solution with taurolidine | ND PARTNERS, LLC | 2004-10-12 | — | — | US | disclosed |
| WO-2003101457-A1 | PERITONEAL DIALYSIS SOLUTION WITH TAUROLIDINE | BIOLINK CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030225066-A1 | Peritoneal dialysis solution with taurolidine | BIOLINK CORPORATION | 2003-12-04 | — | — | US | disclosed |
| US-20020161003-A1 | Method and compositions for the eradication and control of methicillin-resistant staphylococcus aureus bacteria and the prevention of the development of antibiotic drug resistance in said bacteria | MEDPOINTE HEALTHCARE, INC. (A DELAWARE CORP) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027043-A1 | PREPARATION OF ANTIMICROBIAL FORMULATIONS USING 7-OXA-2-THIA-1,5-DIAZABICYCLO[3.3.1]NONANE-2,2-DIONE | THPO, LTA, NONO | LMNA 3453/4885BLM 3178/4885SLC6A6 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.